Akari Therapeutics (AKTX) announced a strategic partnership with WuXi XDC to accelerate the development of Akari’s novel PH1 payload. Akari is working to advance its program, AKTX-101, into a Phase 1 clinical trial expected to initiate in late 2026 or early 2027 subject to regulatory clearance.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTX: